Teva and Lonza Review Biosimilars Opportunity - - BioPharm International

ADVERTISEMENT

Teva and Lonza Review Biosimilars Opportunity



Teva and Lonza have announced that their joint venture will continue to develop, manufacture and market affordable, efficacious and safe biosimilars. The biosimilars arena presents significant opportunities and both companies are set on finding the best routes to realizing the benefits that safe biosimilars of certain biologic pharmaceuticals will bring to the society.

There is, however, significant regulatory uncertainty with biosimilars at present. Teva and Lonza are, therefore, taking a measured approach. Both companies have agreed to fully evaluate the prevailing regulatory and commercial circumstances before making any further long-term investment decisions on their joint venture.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines

Click here